OncLive® On Air S15 Ep44: Subcutaneous Isatuximab via On-Body Injector Has Noninferior Efficacy vs IV Delivery in Myeloma: With Sikander Ailawadhi, MD; and Beth Faiman, CNP, PhD
Jan 30, 2026
Sikander Ailawadhi, MD, a Mayo Clinic myeloma researcher, and Beth Faiman, CNP, PhD, a Cleveland Clinic hematology practitioner, talk about subcutaneous isatuximab delivered via an on-body injector. They cover trial design showing noninferior efficacy to IV, practical advantages like hands-free delivery and fewer reactions, body-weight considerations, home administration pilots, and implications for patient access and convenience.
AI Snips
Chapters
Transcript
Episode notes
OBI Matches IV Efficacy And PK
- The ARACALIA trial showed subcutaneous isatuximab via an on-body injector (OBI) was noninferior to IV for efficacy and pharmacokinetics.
- The OBI had >99% successful injections and similar safety compared with IV administration.
Small-Gauge OBI Lowers Reaction Risk
- The OBI uses a thin 30-gauge hidden needle for low-pressure, hands-free delivery.
- Sub-Q OBI administration produced almost no infusion-related reactions compared with initial IV anti-CD38 infusions.
Body Habitus Could Affect Sub-Q Absorption
- Subcutaneous delivery raises concerns about variable absorption across body habitus versus IV's full bioavailability.
- The study specifically evaluated how BMI extremes might affect drug levels and clinical outcomes.